Three Pathways have emerged in Innovative Access Agreements
The days of simply determining the market demand for a new drug as a function…
Certara2021 年 6 月 11 日
Outcomes Based Agreements
The days of simply determining the market demand for a new drug as a function…
Certara2021 年 6 月 11 日
Your First Choice in Complex Biologics Drug Development
The pharmaceutical has made massive investments in complex biologics, a drug class that includes oligonucleotide…
Certara2021 年 6 月 1 日
De-risk your program with evidence-based secondary pharmacology insights
Safety issues account for about a quarter of the attrition in drug projects and can…
Certara2021 年 5 月 28 日
Stakeholder perspectives: current and potential benefits
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Certara2021 年 5 月 26 日
Strengths and opportunities for HTAs and market access in Europe through case studies
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Certara2021 年 5 月 26 日
Similarities and differences between SNDS and other claim databases
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Certara2021 年 5 月 25 日
Using Authoring Templates to Write the Right Way
Creating submission-ready regulatory documents that are consistent in presentation, appropriate in content, and formatted to…
Certara2021 年 5 月 25 日
Overview of SNDS and the key working practices to access the database and ongoing SNDS developments
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Certara2021 年 5 月 25 日
PBPK modeling approaches to assess risks associated with bioequivalence in drug development
In this webinar, Dr. Ioannis Loisios-Konstantinidis from Novartis, Switzerland discussed: Opportunities and challenges in conducting…
Certara2021 年 5 月 19 日
